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Erectile function and late-onset hypogonadism symptoms
related to lower urinary tract symptom severity in elderly
men
Ozan Bozkurt1, Deniz Bolat2, Omer Demir1, Oktay Ucer3, Ali Şahin4, Burak Ozcift5, Abdulkadir Pektaş6,
Tahir Turan7, Bilal H Gümüş3, Ertan Can8, Ahmet Bolukbasi5, Haluk Erol9 and Adil Esen1
The aim of this study was to evaluate the relationship between lower urinary tract symptoms (LUTSs), erectile dysfunction (ED) and
symptomatic late-onset hypogonadism (SLOH) in ageing men in the Aegean region of Turkey. Five hundred consecutive patients .40
years old who had been in a steady sexual relationship for the past 6 months and were admitted to one of six urology clinics were
included in the study. Serum prostate-specific antigen and testosterone levels and urinary flow rates were measured. All patients filled
out the International Prostate Symptom Score and Quality of Life (IPSS–QoL), International Index of Erectile Function (IIEF) and Aging
Males’ Symptoms (AMS) scale forms. Of the patients, 23.9% had mild LUTSs, 53.3% had moderate LUTSs and 22.8% had severe
LUTSs. The total testosterone level did not differ between groups. Additionally, 69.6% had ED. The presence of impotence increased
with increasing LUTS severity. Symptomatic late-onset hypogonadism (AMS .27) was observed in 71.2% of the patients. The
prevalence of severe hypogonadism symptoms increased with the IPSS scores. A correlation analysis revealed that all three
questionnaire scores were significantly correlated. In conclusion, LUTS severity is an age-independent risk factor for ED and SLOH.
LUTS severity and SLOH symptoms appear to have a strong link that requires etiological and biological clarification in future studies.
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INTRODUCTION
There has been dramatic worldwide increase in the elderly population
during the twentieth century. Thus, in recent years, the symptoms and
complaints of ageing men have found increasing scientific attention.
Increasing age is associated with various physiologic changes in men
such as decreased sexual function and increased voiding problems.
Lower urinary tract symptoms (LUTSs), erectile dysfunction (ED)
and symptomatic late-onset hypogonadism (SLOH) are the most
common urological complaints in elderly men.
There are various large-scale community-based studies showing
the association between LUTSs and ED.1–4 The following theories
have been proposed for the possible pathophysiological links: the
nitric oxide synthase/nitric oxide theory; the autonomic hyperac-
tivity and metabolic syndrome hypothesis; the Rho-kinase activa-
tion/endothelin pathway; and pelvic atherosclerosis.5 However, it
seems difficult to explain the relationship between these two con-
ditions with just one of the above-mentioned theories. All of these
theories may contribute to the development of these conditions in
different stages.
SLOH is a condition composed of different physiological, somatic,
vegetative and sexual complaints due to decreasing androgen levels in
elderly men. The prevalence of hypogonadism in men ranges from
6.0% to 12.3% between the ages of 40 and 69 years, and it is estimated
that 2.4 million men in the United States have androgen deficiency.6
The association between LUTSs and SLOH might be important
because both conditions affect ageing men and the management of
one condition may have an improving effect on the other. However, in
these studies, only a hormonal evaluation was performed for SLOH,
not a symptomatic evaluation.
In this study, we evaluated the relationship between LUTSs, ED and
SLOH in patients presenting with LUTSs in the Aegean region of
Turkey. Validated questionnaires were used for this purpose.
MATERIALS AND METHODS
Participants
Five hundred consecutive patients aged .40 years who had been in a
steady sexual relationship for the past 6 months and were admitted to a
urology clinic with LUTSs were included. All patients gave their
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informed written consent prior to their inclusion in the study. In this
cross-sectional multicentre study, patients with similar profiles were
recruited from six different institutions of the Aegean Region of
Turkey. Patients with genital abnormalities, systemic diseases such
as diabetes mellitus, thyroid diseases or neurological diseases or a
history of transurethral resection or pelvic surgery and patients taking
medication for LUTSs or ED were excluded.
Patient evaluation
After taking a detailed medical history and performing a digital rectal
examination, serum prostate-specific antigen, testosterone levels and
urinary flow rates were measured. Blood samples were drawn between
8:00 and 10:00 a.m. from overnight-fasting patients. For uroflowmetry
studies, the patients were asked to urinate when they had a strong
desire.
Patients were assessed based on the International Index of Erectile
Function (IIEF) for ED, the International Prostate Symptom Score
(IPSS) and the IPSS–Quality of Life (IPSS-QoL) for LUTSs and the
Aging Males’ Symptoms (AMS) scale for ageing male symptoms. The
erectile function (EF) domain consists of questions 1–5 and 15, which
aim to assess EF. ED was diagnosed when the total of the IIEF-EF
domain scores was ,26 points.7 The severity of ED according to the
IIEF-EF score was classified into four categories as severe (1–10),
moderate (11–16) or mild (17–25) ED or no ED (26–30). LUTSs were
classified as mild (IPSS of f7), moderate (IPSS of 8–19) or severe
(IPSS of 20 or more).8 Patients with a total AMS score of at least 27
were considered to have SLOH symptoms.9 SLOH was classified as
mild (AMS of 27–36), moderate (AMS of 37–49) or severe (AMS of 50
or more). The total AMS score and the domain scores, including the
somatic (items: 1–2–3–4–5–9–10), sexual (items: 12–14–15–16–17)
and psychological (items: 6–7–8–11–13) domains, were compared.
At the end of data collection, the patients were divided into three
groups according to the presence of LUTSs.
Statistical analysis
The patient characteristics, laboratory measurements and question-
naire scores, including the IIEF and AMS (total and subscales), were
compared using one-way ANOVA. IIEF and AMS scores were com-
pared between each group by a post-hoc Tukey test. The Pearson x2 test
was used to test the association of ED and SLOH with LUTSs, and
crude odds ratios are given. The relationships between IPSS, AMS and
IIEF scores were compared by the Pearson correlation test. Statistical
significance was defined as P,0.05. The data were analysed using the
Statistical Package for Social Sciences, version 11.0 (SPSS, Chicago, IL,
USA), software program.
RESULTS
A total of 492 patients were included in the statistical analyses. Eight
patients were not included in the statistical analyses due to lack of data.
There was no significant difference between the mean ages of the
moderate and severe LUTS groups, whereas the mild LUTS group
was younger when compared with the other two groups (Table 1).
The total PSA level was higher in patients with severe LUTSs
(P,0.001). The total testosterone level did not differ between groups.
Of the patients, 69.6% had ED. The presence of ED increased with
increasing LUTS severity (x2 likelihood ratio: 6.9, P50.032). The pre-
valence of severe ED also increased with increasing LUTS severity
(Figure 1).
SLOH (AMS .27) was observed in 71.2% of the patients. When the
groups were compared, the SLOH prevalence rates were 54.7%, 72.2%
and 81.1% in the mild, moderate and severe LUTS groups, respec-
tively. There were significant differences between the LUTS groups in
both the total and somatic, sexual and psychological subgroup scores
of the AMS (Table 2). The presence of SLOH increased with increasing
LUTS severity (x2 likelihood ratio: 21.5, P,0.001). The prevalence of
severe SLOH also increased with increasing LUTS severity (Figure 2).
A correlation analysis revealed that all three questionnaire forms
were correlated with each other (Table 3).
Table 1 Comparison of the evaluated parameters between the three groups
LUTS severity
Mild (I) Moderate (II) Severe (III) P
N (%) 118 (24.0) 262 (53.2) 112 (22.8)
Age (year) 56.467.7 58.767.9 60.268.4 0.001a
Prevalence of ED (%) 60.7 69.9 75.7 0.027
IIEF-EF 20.768.6 18.469.2 15.769.8 ,0.001b
MFR (ml s21) 19.5616.9 14.666.9 13.0611.2 ,0.001a
IPSS–QoL 1.761.2 3.161.2 4.161.0 ,0.001c
PSA (ng ml21) 1.561.5 1.961.8 2.562.4 ,0.001b
Testosterone (ng ml21) 464.56151.3 468.56161.8 456.06153.9 0.795
Abbreviations: ED, erectile dysfunction; IIEF-EF, International Index of Erectile Function-Erectile Function; IPSS-QoL, International Prostate Symptom Score-Quality of
Life; LUTS, lower urinary tract symptom; MFR, maximum flow rate; PSA: prostate-specific antigen.
a Between I–II and I–III.
b Between I–III and II–III.
c Between I–II, I–III and II–III.
Figure 1 Relationship between LUTS severity with ED prevalence. The severity of
ED is directly correlated with LUTS severity. ED, erectile dysfunction; LUTS, lower
urinary tract symptoms.
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DISCUSSION
Ageing is a known predominant risk factor for both male sexual dys-
function and LUTSs. The ‘Massachusetts Male Aging Study’ was the
first to explore risk factors for ED in a large population.10 This study
provided very valuable information about the basic risk factors for ED.
According to this study, systemic diseases such as diabetes, hyperten-
sion, cardiovascular diseases and depression were age-independent
risk factors for ED. However, LUTSs was not evaluated as a possible
risk factor for ED in that study. In the population-based ‘Cologne
Male Survey’, Braun et al.1 evaluated the relationship between
LUTSs and ED with validated questionnaires by postal mail. They
reported that sexual activity decreased and that ED prevalence
increased with ageing. When they compared ED patients with non-
ED patients, the LUTS prevalence rates were 72.2% and 37.7% for the
ED and non-ED groups, respectively. They proposed LUTSs as an
independent risk factor for ED, as they demonstrated that patients
with LUTSs had an odds ratio of 2.11 when compared with patients
who did not have LUTSs.
One of the largest community-based studies, the ‘Multinational
Survey of the Aging Male’ (MSAM-7), evaluated the relationship
between LUTSs and sexual function in 12 815 men aged 50–80 years
in seven developed countries.2 They found that sexual activity
decreased with increasing age and LUTS severity. LUTS severity was
also highly predictive for all domains (EF, intercourse satisfaction,
orgasmic function, sexual desire and overall satisfaction) of the IIEF
questionnaire, and the IIEF domain scores decreased with increasing
LUTS severity. They also demonstrated that LUTSs were a stronger
predictor of male sexual dysfunction compared to other risk factors
such as diabetes mellitus, hypertension, hyperlipidaemia and cardiac
diseases. In the present study, the overall prevalence of ED was 69.6%
when defined as an IIEF-EF score ,26. This finding is similar to those
of the studies referenced above. When we consider the effects of LUTS
severity, we found that ED prevalence and severity increased with
increasing LUTS severity in agreement with previous studies.
Additionally, when moderate and severe LUTS groups were com-
pared, the IIEF-EF scores were significantly lower in the severe
LUTS group, although no significant difference was found between
the ages of these two groups. Our findings demonstrate that LUTS
severity is an age-independent risk factor for ED.
SLOH is a condition characterized by various sexual, psychological
and physiological symptoms affecting elderly men, primarily due to
androgen levels decreasing with ageing. The ‘International Society for
the Study of the Aging Male’ defined SLOH as a biochemical syndrome
caused by a decrease in testosterone that occurs with ageing.11,12 Some
intriguing studies have highlighted the role of sex steroids in the struc-
ture and function of the urinary tract, although the studies have pri-
marily been performed in animals.13 These studies have identified
androgen and oestrogen receptors in the urothelium and smooth
muscle cells of the urethra and bladder in rats and rabbits as well as
in the neurons in the autonomic ganglia of the prostatic plexus of male
rats.14,15 Upon castration, the electrically evoked relaxation of the
smooth muscle of the prostatic urethra was decreased.16 The Rho-
kinase activation/endothelin pathway may be involved in the
increased smooth muscle activity found in LUTSs/benign prostate
hyperplasia.17 Additionally, nitric oxide appears to have a smooth
muscle relaxant effect on the urogenital organs.13
Few studies have analysed the relationship between circulating tes-
tosterone and LUTSs. Litman et al.18 reported a relationship between
LUTSs and plasma total testosterone and bioavailable testosterone,
but this relationship disappeared after adjusting for age. Rohrmann
et al.19 evaluated the effect of circulating sex steroid hormones on
LUTSs and concluded that androstanediol glucuronide, a metabolite
of dihydrotestosterone and oestradiol were associated with an
increased risk of LUTSs. Kim et al.20 investigated the relationship
between sex hormone levels and LUTSs in patients with benign pro-
state hyperplasia, and they reported that endogenous testosterone may
have a beneficial effect on lower urinary tract function and that a high
frequency of nocturia may induce testosterone deficiency. In another
study, Liao et al.21 showed that most IPSS items showed no significant
association with serum sex hormone levels, except for nocturia, which
showed a negative correlation with the serum testosterone level. In
Table 2 Comparison of AMS scores between the three groups
LUTS severity
Mild (n5118) Moderate (n5262) Severe (n5112) P
SLOH prevalence (%) 54.7 72.2 81.1
AMStotal 29.769.7 33.069.9 38.4612.2 ,0.001
AMSsomatic 11.664.5 12.764.8 15.765.8 ,0.001
AMSsexual 9.163.7 10.764.2 11.764.3 ,0.001
AMSpsychological 8.664.0 9.064.2 10.864.8 ,0.001
Abbreviations: AMS, Aging Males’ Symptoms; LUTS, lower urinary tract symptom; SLOH, symptomatic late-onset hypogonadism.
Figure 2 Relationship between LUTS severity and LOH symptoms. LOH symp-
tom severity increases with increasing LUTS scores. LUTS, lower urinary tract
symptoms; SLOH, symptomatic late-onset hypogonadism.
Table 3 Correlations of questionnaire forms*
IPSStotal IPSSvoiding IPSSstorage IIEF-EF
AMStotal 0.306 0.267 0.267 0.417
AMSsomatic 0.289 0.271 0.244 20.245
AMSsexual 0.238 0.211 0.210 20.569
AMSpsychological 0.194 0.168 0.185 20.216
IIEF-EF 20.240 20.181 20.259
Abbreviations: AMS, Aging Males’ Symptoms; IIEF-EF, International Index of
Erectile Function-Erectile Function; IPSS, International Prostate Symptom Score.
* r values are provided in the table. All P values were ,0.001.
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contrast, Schatzl et al.22 reported that hypogonadism had no sig-
nificant effect on symptom scores and flow rates in men with
LUTSs. In another study, Miwa et al.23 reported that LUTSs were
not associated with serum total testosterone and free testosterone
levels, although the storage symptom scores of the IPSS were affec-
ted by the serum dehydroepiandrosterone sulphate level in older
men. Interestingly, in our study, the mean serum testosterone levels
did not differ between the mild, moderate and severe LUTS groups,
despite symptomatic differences.
In the above-mentioned studies, only a hormonal evaluation was
performed for SLOH, and a symptomatic assessment was not per-
formed. In many studies, the symptomatic relationship between
LUTSs and LOH has been analysed using testosterone replacement
therapy (TRT). TRT is indicated in the presence of both clinical symp-
toms suggestive of hormone deficiency and a decreased testosterone
level.12,24 Although several testosterone formulations are available,
topical testosterone gels and long-term depot injections are the most
commonly used treatment options due to their favourable pharma-
cokinetic profiles, characterized by relatively constant plasma levels,
avoiding wide fluctuations and minimal side effects.25 Amano et al.26
evaluated the efficacy of TRT using testosterone ointment (Glowmin)
for LUTSs in LOH patients. They reported that serum free testosterone
levels and the scores for the four parameters of the AMS, six of eight
domains in the 36-Item Short Form Health Survey (SF-36), the IIEF-5
and the total IPSS improved significantly after 3 months of TRT. They
demonstrated that the voiding disturbance improved more than the
storage disturbance. Karazindiyanoglu and Cayan27 reported that
TRT with transdermal testosterone 50–100 mg of gel per day for 1
year significantly improved bladder function by increasing bladder
capacity and compliance and decreasing detrusor pressure at maximal
flow in 25 patients with SLOH. Kalinchenko et al.28 showed that TRT
with either daily testosterone gel (50 mg) application or injections of
1000 mg of testosterone undecanoate also improved many para-
meters, including plasma testosterone levels, the IPSS, the AMS scale
and the IIEF, in LOH men. Recently, Shigehara et al.29 reported a
randomized controlled study evaluating the effects of ART on
LUTSs in 52 hypogonadal men with mild BPH. Fifty-two patients were
randomly assigned to receive testosterone (ART group 26 patients) as
250 mg of testosterone enanthate every 4 weeks or to the untreated
control group (26 patients), and the IPSS, UFM data and PVR were
compared at baseline and 12 months after treatment. At the 12-month
visit, the IPSS showed a significant decrease compared with baseline,
and the maximum flow rate and voided volume showed significant
improvements in the TRT group; no significant improvements were
observed in the controls. However, Takao et al.30 reported that the
efficacy of TRT by testosterone or HCG injection was questionable.
Additionally, recent guidelines on TRT note that the diagnosis or
suspicion of prostate cancer and severe LUTSs due to BPH are relative
contraindications to TRT.31,32
To the best of our knowledge, our study is the first in the literature
to compare AMS scores with LUTS severity. Atan et al.33 found no
significant correlation between total AMS scores and ageing in their
study in which they evaluated the effects of ageing on LUTSs, EF and
SLOH. However, they did not report the relationship between LUTS
severity and SLOH symptoms. In a recent study, the relationships
between LUTSs, ED and depression in Japanese patients with SLOH
were investigated. That study revealed that moderate and severe ED
was correlated with depression, whereas LUTSs were not related to
depression in Japanese SLOH patients.34 We found the prevalence of
SLOH to be 71.2% in men with LUTSs in the present study. We also
determined that the SLOH prevalence increased with increasing LUTS
severity. When the AMS subscales in three groups were examined, we
also determined that LUTS severity has a detrimental effect on all
subscales of the AMS and the total AMS score. When patients with
SLOH were compared with patients without SLOH, the total IPSS and
the IPSS voiding and storage symptom scores were all significantly
higher in patients with SLOH.
There are some limitations to our study. First, serum-free and bio-
available T levels were not measured due to the multi-institutional
nature of the study, although they may differ between groups. Second,
we evaluated only patients presenting with urinary symptoms to uro-
logy clinics, and our study does not refer to the relationships between
LUTSs, ED and SLOH in the general population.
CONCLUSIONS
In this multicentre, cross-sectional analysis of LUTSs, ED and
SLOH, LUTS severity was an age-independent risk factor for ED
and SLOH. Patients with severe LUTSs were more likely to have ED
and SLOH compared with patients with mild and moderate LUTS.
Additionally, the prevalence of severe ED and SLOH increased with
increasing LUTS severity. Furthermore, validated forms of ED, LUTSs
and SLOH were associated with each other in patients with LUTS. We
also suggest that LUTS severity and SLOH symptoms are closely asso-
ciated, although this hypothesis requires etiological and biological
clarification in future studies with large sample sizes.
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